Skip to main content
Skip to main content
MYO logo

Myomo, Inc. (MYO)

$0.71 $-0.01 (-1.64%) |BUY · 62 · B+
MCap: 28M| Vol: 432K| Target: $1.10 (+55.1%)
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Myomo, Inc. (MYO) trades at $0.71 with AI Score 62/100 (Hold). Myomo, Inc. is a wearable medical robotics company specializing in myoelectric orthotics for individuals with neuromuscular disorders. Market cap: 28M, Sector: Healthcare.

Last analyzed: Feb 8, 2026
Myomo, Inc. is a wearable medical robotics company specializing in myoelectric orthotics for individuals with neuromuscular disorders. Their flagship product, MyoPro, enhances upper limb function for those with weakened or paralyzed arms.

MYO stock analysis for 2026: Analysts have set a consensus price target of $1.10 for Myomo, Inc., suggesting 55.1% upside from the current price of $0.71. The AI MoonshotScore is 62/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Council Score · 8-Perspective Consensus
BUY 62/100 · B+

MYO: 1/1 perspectives are bullish.

Munger's Mindset · Balance Sheet & Valuation
Financial Health
No Data
Margin of Safety
No Data
Council Score · 8 perspectives · See tabs for details →

Myomo, Inc. (MYO) Healthcare & Pipeline Overview

CEOPaul R. Gudonis
Employees184
HeadquartersBoston, MA, US
IPO Year2017

Myomo, Inc. pioneers wearable medical robotics with MyoPro, a myoelectric orthosis empowering individuals with neuromuscular disorders to regain upper limb function and independence, targeting a significant unmet need in rehabilitation and assistive technology with a $0.03B market cap.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Feb 8, 2026

What Is the Investment Thesis for MYO?

Myomo presents a notable research candidate within the medical device sector, driven by its innovative MyoPro orthosis and a growing market for assistive technologies. The company's focus on addressing upper limb paralysis in individuals with neuromuscular disorders positions it to capitalize on a significant unmet need. Key value drivers include expanding sales through the Veterans Health Administration, rehabilitation hospitals, and strategic partnerships with orthotics and prosthetics providers. Growth catalysts include increasing awareness of MyoPro's benefits among healthcare professionals and patients, securing additional insurance coverage, and expanding into new geographical markets. While the company currently operates with a negative profit margin of -28.9%, the high gross margin of 66.6% indicates the potential for profitability as sales volume increases. Investors may want to evaluate Myomo's potential for long-term growth and its positive impact on patients' lives.

Based on FMP financials and quantitative analysis

MYO Key Highlights

  • Market Cap of $0.03B reflects the company's current valuation and growth potential within the medical device market.
  • Gross Margin of 66.6% indicates strong pricing power and efficient production of MyoPro orthotics.
  • Negative P/E Ratio of -2.82 suggests the company is currently not profitable, but reflects investment in growth and development.
  • Beta of 1.16 indicates the stock is slightly more volatile than the market, reflecting its growth-oriented nature.
  • Focus on the Veterans Health Administration provides a stable revenue stream and access to a large patient population.

Who Are MYO's Competitors?

What Are MYO's Key Strengths?

  • Innovative MyoPro technology addresses a significant unmet need.
  • Established presence within the Veterans Health Administration.
  • High gross margin indicates strong pricing power.
  • Focus on improving patient outcomes and quality of life.

What Are MYO's Weaknesses?

  • Currently operating with a negative profit margin.
  • Limited brand awareness compared to larger medical device companies.
  • Reliance on third-party distributors and O&P providers.
  • Relatively small market capitalization.

What Could Drive MYO Stock Higher?

  • Expansion of insurance coverage for MyoPro, increasing accessibility for patients.
  • Continued growth in sales through the Veterans Health Administration.
  • Launch of next-generation MyoPro orthotics with enhanced features.
  • Strategic partnerships with leading orthotics and prosthetics providers.
  • Positive clinical trial results demonstrating the effectiveness of MyoPro.

What Are the Key Risks for MYO?

  • Competition from larger medical device companies with greater resources.
  • Technological advancements that could render MyoPro obsolete.
  • Dependence on third-party distributors and O&P providers.
  • Changes in healthcare regulations and reimbursement policies.
  • Economic downturn affecting patient affordability.

What Are the Growth Opportunities for MYO?

  • Expansion within the Veterans Health Administration (VHA): Myomo has established a presence within the VHA, providing MyoPro to veterans with upper limb paralysis. Expanding this relationship through increased awareness and adoption within VHA hospitals and clinics represents a significant growth opportunity. The VHA serves a large patient population with neuromuscular disorders, offering a stable and recurring revenue stream for Myomo. Securing additional contracts and expanding the range of covered conditions within the VHA can drive substantial growth in the coming years.
  • Strategic Partnerships with Orthotics and Prosthetics (O&P) Providers: Collaborating with O&P providers is crucial for reaching patients and facilitating the fitting and training process for MyoPro. Establishing strategic partnerships with leading O&P clinics across the United States can expand Myomo's market reach and enhance its distribution network. These partnerships provide access to established patient referral pathways and expertise in orthotic and prosthetic care, accelerating adoption and improving patient outcomes. This growth driver can be realized within the next 1-3 years.
  • Securing Broader Insurance Coverage: Obtaining broader insurance coverage for MyoPro is essential for increasing affordability and accessibility for patients. Working with insurance companies to demonstrate the clinical and economic benefits of MyoPro can lead to expanded coverage policies. This involves conducting clinical trials, publishing research findings, and engaging with payers to highlight the value proposition of MyoPro. Successful expansion of insurance coverage can significantly increase the addressable market and drive sales growth over the next 2-5 years.
  • Development of Next-Generation Myoelectric Orthotics: Investing in research and development to create next-generation myoelectric orthotics can enhance Myomo's product offerings and maintain its competitive edge. This includes incorporating advanced sensor technology, improving the device's functionality and comfort, and expanding its applications to address a wider range of neuromuscular conditions. Continuous innovation and product development are crucial for sustaining long-term growth and attracting new customers. This is an ongoing effort with potential for incremental improvements and new product launches in the coming years.
  • Geographic Expansion into International Markets: Expanding into international markets represents a significant growth opportunity for Myomo. Identifying countries with a high prevalence of neuromuscular disorders and a favorable regulatory environment can drive international sales. This involves establishing partnerships with local distributors, adapting the MyoPro device to meet local standards, and conducting clinical trials to demonstrate its effectiveness in diverse populations. International expansion can diversify revenue streams and unlock new growth opportunities over the next 3-5 years.

What Opportunities Does MYO Have?

  • Expanding insurance coverage for MyoPro.
  • Developing next-generation myoelectric orthotics.
  • Geographic expansion into international markets.
  • Strategic partnerships with leading rehabilitation centers.

What Threats Does MYO Face?

  • Competition from established medical device companies.
  • Technological advancements that could render MyoPro obsolete.
  • Changes in healthcare regulations and reimbursement policies.
  • Economic downturn affecting patient affordability.

What Are MYO's Competitive Advantages?

  • Proprietary myoelectric technology in the MyoPro orthosis.
  • Established relationships with the Veterans Health Administration.
  • Specialized expertise in wearable medical robotics.
  • Strong gross margin indicating pricing power.

What Does MYO Do?

Myomo, Inc., founded in 2004 and headquartered in Boston, Massachusetts, is a medical robotics company focused on designing, developing, and producing myoelectric orthotics. The company's core product, MyoPro, is a myoelectric-controlled upper limb brace that supports and improves the functionality of weak or paralyzed arms. This innovative technology enables individuals with neuromuscular conditions to perform activities of daily living more effectively. MyoPro is designed for adults and adolescents affected by conditions such as brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. Myomo distributes its products through a network of orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals, and distributors. The company's mission is to restore independence and improve the quality of life for individuals with upper limb paralysis through advanced medical robotics. Myomo operates primarily in the United States, addressing a critical need for assistive technology in the rehabilitation and healthcare sectors. The company's focus on innovation and patient-centric solutions positions it as a key player in the wearable medical robotics market.

What Products and Services Does MYO Offer?

  • Designs and develops myoelectric orthotics.
  • Produces the MyoPro, an upper limb brace controlled by myoelectric signals.
  • Provides assistive technology for individuals with neuromuscular disorders.
  • Improves functional activities of daily living for patients with weak or paralyzed arms.
  • Sells products to orthotics and prosthetics providers.
  • Partners with the Veterans Health Administration to provide MyoPro to veterans.
  • Distributes products through rehabilitation hospitals and distributors.

How Does MYO Make Money?

  • Direct sales to orthotics and prosthetics providers.
  • Sales through the Veterans Health Administration.
  • Distribution through rehabilitation hospitals.
  • Partnerships with distributors to expand market reach.

What Industry Does MYO Operate In?

Myomo operates within the medical device industry, specifically in the market for wearable robotics and assistive technologies. This sector is experiencing growth driven by an aging population, increasing prevalence of neurological disorders, and advancements in robotics and sensor technology. The competitive landscape includes companies developing exoskeletons, orthotics, and prosthetics. Myomo differentiates itself with its myoelectric-controlled MyoPro orthosis, designed specifically for upper limb paralysis. The industry is characterized by stringent regulatory requirements, technological innovation, and a focus on improving patient outcomes. The global market for medical robotics is projected to reach billions of dollars in the coming years, presenting significant growth opportunities for companies like Myomo.

Who Are MYO's Key Customers?

  • Individuals with neuromuscular disorders (stroke, brachial plexus injury, etc.).
  • Orthotics and prosthetics providers.
  • Veterans Health Administration.
  • Rehabilitation hospitals.
AI Confidence: 72% Updated: Feb 8, 2026

MYO Financials

MYO Latest News

MYO Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MYO.

Price Targets

Consensus target: $1.10

MYO MoonshotScore

62/100

What does this score mean?

The MoonshotScore rates MYO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Myomo, Inc. Healthcare Stock: Key Questions Answered

What does Myomo, Inc. do?

Myomo, Inc. is a wearable medical robotics company that specializes in the design, development, and production of myoelectric orthotics. Their primary product, MyoPro, is a myoelectric-controlled upper limb brace designed to support and improve the function of weak or paralyzed arms. This technology helps individuals with neuromuscular disorders, such as those resulting from stroke, brachial plexus injury, or spinal cord injury, to perform daily activities more effectively. Myomo sells its products through orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals, and distributors, focusing on improving the quality of life for patients with upper limb paralysis.

Is MYO stock worth researching?

MYO stock represents a speculative investment opportunity with high growth potential but also significant risks. The company's innovative MyoPro technology and established presence within the Veterans Health Administration are positive factors. However, the company's negative profit margin and small market capitalization warrant caution. Investors should carefully consider the company's growth prospects, competitive landscape, and financial performance before investing. While the high gross margin suggests potential for future profitability, the company needs to demonstrate sustainable revenue growth and cost management to justify a positive investment outlook. A balanced approach considering both the potential upside and inherent risks is essential.

What are the main risks for MYO?

Myomo faces several key risks, including competition from larger medical device companies with greater resources, the potential for technological advancements to render MyoPro obsolete, and dependence on third-party distributors and O&P providers. Changes in healthcare regulations and reimbursement policies could also negatively impact the company's revenue. Additionally, an economic downturn could affect patient affordability and demand for MyoPro. The company's current financial performance, including its negative profit margin, also poses a risk. Investors should carefully assess these risks and consider their potential impact on Myomo's future performance.

What are the key factors to evaluate for MYO?

Myomo, Inc. (MYO) currently holds an AI score of 62/100, indicating moderate score. Analysts target $1.10 (+55% from $0.71). Key strength: Innovative MyoPro technology addresses a significant unmet need. Primary risk to monitor: Competition from larger medical device companies with greater resources. This is not financial advice.

How frequently does MYO data refresh on this page?

MYO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven MYO's recent stock price performance?

Recent price movement in Myomo, Inc. (MYO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $1.10 implies 55% upside from here. Notable catalyst: Innovative MyoPro technology addresses a significant unmet need. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider MYO overvalued or undervalued right now?

Determining whether Myomo, Inc. (MYO) is overvalued or undervalued requires examining multiple metrics. Analysts target $1.10 (+55% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying MYO?

Before investing in Myomo, Inc. (MYO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Financial data is based on the most recent available information.
  • Market analysis is based on current industry trends and forecasts.
  • This analysis is for informational purposes only and does not constitute investment advice.
Data Sources

Popular Stocks